Exercise of options, PDMR dealing and TVR

RNS Number : 5752Y

ReNeuron Group plc

09 May 2019

 

 

9 May 2019

AIM: RENE

ReNeuron Group plc

Exercise of options, PDMR dealing and

total voting rights

 

ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that it has received notices to exercise options from certain PDMRs of the Company to subscribe for a total of 65,792 new ordinary shares of 1 pence each in the Company ("Ordinary Shares").

On 9 May 2019, Sharon Grimster, VP Development and General Manager Wales, exercised options over 39,960 Ordinary Shares at an exercise price of 100 pence per share. Subsequently, on 9 May 2019, Mrs Grimster sold 39,960 Ordinary Shares at a share price of 267 pence.

On 9 May 2019, Dr Randolph Corteling, Head of Research, exercised options over 25,832 Ordinary Shares at an exercise price of 100 pence per share. Subsequently, on 9 May 2019, Dr Corteling sold 25,832 Ordinary Shares at a share price of 267 pence.

Total voting rights

Following the issue of 65,792 Ordinary Shares pursuant to the exercise of options described above, together with exercise of options by other staff under its existing blocklisting arrangements, the Company has 31,799,617 ordinary shares of 1 pence each in issue, all with voting rights. The Company holds no ordinary shares in treasury. The above figure of 31,799,617 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.

ENDS

ENQUIRIES:

ReNeuron	[phone]
Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan	[phone]
Mark Court, Sophie Wills, Tilly Abraham
Stifel Nicolaus Europe Limited	[phone]
Jonathan Senior, Stewart Wallace, Ben Maddison
(NOMAD and Joint Broker)
N+1 Singer	[phone]
Aubrey Powell, Mark Taylor (Joint Broker)

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's lead clinical-stage candidates are in development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.  ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action.  ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com.

The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation and provide further detail.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Sharon Grimster
2	Reason for the notification
a)	Position/status	VP Development and General Manager Wales
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ReNeuron Group plc
b)	LEI	2138003TU12CQ5TZO137
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares of 1 pence each RENE - GB00BF5G6K95
b)	Nature of the transaction	Exercise of options over ordinary shares
c)	Price(s) and volume(s)	Price(s)  Volume(s) 100 pence 39,960
d)	Aggregated information	N/A
e)	Date of the transaction	09 May 2019
f)	Place of the transaction	London Stock Exchange, AIM Market

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Sharon Grimster
2	Reason for the notification
a)	Position/status	VP Development and General Manager Wales
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ReNeuron Group plc
b)	LEI	2138003TU12CQ5TZO137
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares of 1 pence each RENE - GB00BF5G6K95
b)	Nature of the transaction	Sale of ordinary shares
c)	Price(s) and volume(s)	Price(s)  Volume(s) 267 pence 39,960
d)	Aggregated information	N/A
e)	Date of the transaction	09 May  2019
f)	Place of the transaction	London Stock Exchange, AIM Market

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Randolph Corteling
2	Reason for the notification
a)	Position/status	Head of Research
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ReNeuron Group plc
b)	LEI	2138003TU12CQ5TZO137
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares of 1 pence each RENE - GB00BF5G6K95
b)	Nature of the transaction	Exercise of options over ordinary shares
c)	Price(s) and volume(s)	Price(s)  Volume(s) 100 pence 25,832
d)	Aggregated information	N/A
e)	Date of the transaction	09 May 2019
f)	Place of the transaction	London Stock Exchange, AIM Market

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Randolph Corteling
2	Reason for the notification
a)	Position/status	Head of Research
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ReNeuron Group plc
b)	LEI	2138003TU12CQ5TZO137
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares of 1 pence each RENE - GB00BF5G6K95
b)	Nature of the transaction	Sale of ordinary shares
c)	Price(s) and volume(s)	Price(s)  Volume(s) 267 pence 25,832
d)	Aggregated information	N/A
e)	Date of the transaction	09 May  2019
f)	Place of the transaction	London Stock Exchange, AIM Market

 

END

 

 

MSCEAKSNEEANEFF